2-(5-Bromothiophen-2-yl)acetaldehyde | 722536-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-(5-Bromothiophen-2-yl)acetaldehyde
• CAS: 722536-02-9
• 化学式: C₆H₅BrOS
• 分子量: 205.075
• InChiKey: GGTKHMOWCPIXPP-UHFFFAOYSA-N

物化性质

• 沸点：
  265.1±25.0 °C(Predicted)
• 密度：
  1.637±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-氨基-吡唑-3-甲酸乙酯 、 2-(5-Bromothiophen-2-yl)acetaldehyde 在 三乙酰氧基硼氢化钠 作用下， 以 1,1-二氯乙烷 为溶剂， 反应 0.33h， 生成
  参考文献：
  名称：

  5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b

  摘要：

  A series of 5-N,N-disubstituted-5-aminopyrazole-3-carboxylic acids were prepared and found to act as highly potent and selective agonists of the G-Protein Coupled Receptor (GPCR) GPR109b, a low affinity receptor for niacin and some aromatic D-amino acids. Little activity was observed at the highly homologous higher affinity niacin receptor, GPR109a. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.108

文献信息

• [EN] 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER<br/>[FR] 2-ACYLAMINOTHIAZOLES POUR LE TRAITEMENT DU CANCER
  申请人：UNIV MILANO BICOCCA

  公开号：WO2015001024A1

  公开（公告）日：2015-01-08

  The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

  本发明涉及如下所述的化学式(I)的致癌蛋白激酶ALK的抑制剂及其药物组合物。化学式(I)的化合物在制备药物方面是有用的，特别是用于癌症治疗。
• [EN] PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDINE EN TANT QU'INHIBITEURS DE LA TUBERCULOSE
  申请人：VERTEX PHARMA

  公开号：WO2011019405A1

  公开（公告）日：2011-02-17

  The present invention relates to compounds II useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the invention.

  本发明涉及化合物II，用作治疗结核病的抑制剂。该发明还提供了制备本发明化合物的方法。
• [EN] AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS D'AMINOISOXAZOLINE EN TANT QUE RÉCEPTEURS NICOTINIQUES ALPHA7 DE L'ACÉTYLCHOLINE
  申请人：FORUM PHARMACEUTICALS INC

  公开号：WO2017069980A1

  公开（公告）日：2017-04-27

  The present invention relates to novel aminoisoxazoline compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及新型氨基异噁唑啉化合物及其药物组合物，适用作α7-nAChR的激动剂或部分激动剂，以及制备这些化合物和组合物的方法，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物，特别是将该化合物或组合物用于需要的患者的给药方法，例如患有认知缺陷和/或希望增强认知功能的患者，可能从中获益。
• [EN] THIOPHENE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES DE THIOPHENE, LEUR FABRICATION ET LEUR UTILISATION COMME AGENTS PHARMACEUTIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005121134A1

  公开（公告）日：2005-12-22

  Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式（I）化合物，它们的药用盐、对映体形式、二对映异构体和拉克酸盐，上述化合物的制备，含有它们的药物以及其制造，以及上述化合物在控制或预防癌症等疾病中的应用。
• [EN] CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS DE CYCLOPENTATHIOPÈNE DU RÉCEPTEUR GLUCOCORTICOÏDE, AP-1, ET/OU ACTIVITÉ NF-KAPPA B ET UTILISATION DE CEUX-CI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009158380A1

  公开（公告）日：2009-12-30

  A compound of Formula( I ) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing compounds of Formula I and methods of treating diseases or disorders including metabolic and inflammatory or immune associated diseases or disorders.

  一种具有Formula（I）的化合物及其对映体、非对映体异构体和药用可接受的盐，其中R1、R2、R3、R4、R5、R6、R7和R8的定义如本文所述。还公开了含有Formula I化合物的药物组合物和药物组合物，以及治疗包括代谢性、炎症性或免疫相关疾病或疾病的方法。